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ABSTRACT
The prevalence of PCOS was investigated in many studies in different continents. 
However, there is no established prevalence of PCOS for distinct ethnic groups. 
In the current analysis, we conducted searches in PubMed, The Cochrane Library, 
EMBASE, CINAHL up to Jan. 2017 to identify studies reporting prevalence of PCOS in 
the general female population. Forty-two studies were identified, with 13 eligible for 
evidence synthesis. The prevalence among different ethnicity was estimated using 
random effect modelling. Our results suggested the lowest prevalence in Chinese 
women(2003 Rotterdam criterion: 5.6% 95% interval: 4.4–7.3%), and then in an 
ascending order for Caucasians (1990 NIH criterion: 5.5% 95% interval: 4.8–6.3%), 
Middle Eastern (1990 NIH 6.1% 95% interval: 5.3–7.1%; 2003 Rotterdam 16.0% 
95% interval: 13.8–18.6%; 2006 AES 12.6% 95% interval: 11.3–14.2%), and Black 
women (1990 NIH: 6.1% 95% interval: 5.3–7.1%).There is variation in prevalence 
of PCOS under different diagnostic criteria and across ethnic groups. This emphasises 
the need for ethnicity-specific guidelines for PCOS to prevent under- or over-diagnosis 
of the condition given that under-diagnosis may lead to rapid conversion of metabolic 
disorders for patients whereas over-diagnosis may exert negative psychological 
effects on patients which worsens the major symptoms of PCOS.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a 
heterogeneous endocrine disorder, leading to several 
health complications, including menstrual dysfunction, 
infertility, hirsutism, acne, obesity, and metabolic 
syndrome [1]. However, its pathophysiology remains 
largely unknown but many believe that PCOS appears 
to be familial, with its various aspects differentially 
inherited from one generation to the next [2]. Although 
more than 100 candidate genes have been investigated, 
and the potential for gene discovery to improve diagnosis 
and treatment of PCOS is promising, there is much to be 
done before the current findings can be applied in clinical 
practice [3, 4]. The three major diagnostic criteria of 
PCOS widely followed are criteria raised by National 
Institutes of Health(NIH) [5], 2003 Rotterdam Consensus 
raised by European Society of Human Reproduction 
and Embryology (ESHRE) and American Society for 
Reproductive Medicine (ASRM) [6, 7] and criteria raised 
by Androgen Excess Society (AES) [8]. 
It is known that based particularly on ancestry and 
geographic segregation, the world's populations vary in 
physical, behavioural and social distinctiveness due to 
natural selection of genes and adaptation to environmental 
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conditions, which then influences disease phenotype. 
There is emerging evidence that ethnicity is closely 
associated with PCOS phenotype due to different genetic 
and environmental propensity to metabolic and hormonal 
aberrations [9–11]. As early as in 1992, it was found that 
obesity and hirsutism are associated with some genetic 
factors [12], and consequently, the ethnic background 
of women with PCOS needs to be considered in studies 
that investigate the metabolic parameters [13]. A new 
study has suggested that Hispanic women with PCOS 
generally present the most severe phenotype both in terms 
of hyperandrogenism and metabolic features whereas non-
Hispanic Black women demonstrate an overall milder 
clinical presentation of PCOS than Hispanics and non-
Hispanic White women with respect to some aspects [14]. 
Ethnicity-specific guidelines of PCOS are 
potentially in need to identify anthropometric thresholds 
and phenotypic expression for better screening and 
diagnosis in high-risk ethnic groups [15, 16]. However, to 
our knowledge, the prevalence of PCOS in distinct ethnic 
groups has not been established. To address this issue, we 
therefore, performed a comprehensive literature review 
to collect relevant studies and establish the prevalence 




Our search initially produced 4354 citations in total, 
and 45 studies were identified. We excluded 2 presentation 
posters as these studies did not appear to have been 
published in peer reviewed journals. One study was also 
excluded after full-text screening because it evaluated 
prevalence of PCOS in patients with type 2 diabetes 
mellitus. Figure 1 presents a consort diagram summarising 
our search.
Characteristics of prevalence studies
We found 42 studies (see Supplementary Table 1) 
evaluating the prevalence of PCOS but we only retrieved 
the full text for 40 of them, with the remaining 2 articles 
inaccessible [17, 18]: there were no links to follow on the 
PubMed for these two articles. However, in the abstracts 
of these articles, Jiao et al. [17] clearly presented source 
of recruitment, sample size, age range, ethnicity, definition 
of PCOS, prevalence data and the corresponding crude 
number of PCOS cases; Sung et al. [18] provided source 
of recruitment, age range, definition of PCOS, prevalence 
data, with the crude number of PCOS cases and sample 
size irretrievable. 
Geographically speaking, there were 10 studies in 
Americas, 7 in Europe, 11 in Asia, 10 in Middle East and 4 
in Oceania. The sample size ranged from 50 to 12171830. 
Prevalence data for different ethnicity 
Studies scoring 5 and above were evaluated 
to examine the eligibility of inclusion in our model 
(n = 27). Studies that did not fit the general pattern as the 
majority of other studies in the same category were further 
excluded. For example, Lauritsen et al. [19] was removed 
due to the fact that all the other four studies in the Europe 
used the 1990 NIH while it followed the 2003 Rotterdam. 
Hashemipour et al., [20], Mehrabian et al., [21], Asgharnia 
et al., [22] and Musmar et al., [23] were excluded because 
the age range of the sample population was much narrower 
(i.e. 17–18yrs) compared with the rest studies in Middle 
East region. Zhuang et al. [24]was also removed for using 
a wider than reproductive age range (12–44 years), with 
the prevalence of PCOS peaking at the age band of 15–19 
years. Statistical modelling was not performed for South 
Asians (India and Sri Lanka) and Australians because all 
studies in the same region used different age ranges (i.e. 
15–18 yrs, 18–24 yrs). As a result, in terms of age, all the 
studies considered for our statistical modelling included 
study population with an age range of either 17–45, 
18–45, 19–45 years or a median between 27 and 33, with 
an inter-quartile range of 9–13 which can be approximated 
to reproductive age range (see studies with an asterisk in 
Supplementary  Table 1). It should also be noted that we 
did not model prevalence for certain ethnic groups (i.e. 
Mexicans, Thai) as there was only one study available. 
The reason for this is that if the result in a single study is 
spontaneous and unreliable we have no choice but to use it 
as our “best estimate”, which is undoubtedly questionable. 
It was also spotted that the prevalence and the crude 
number of PCOS cases do not match under the 2006 AES 
criteria described by Mehrabian et al. [21]. 
After further investigation of features of each 
available study, we noticed that some studies used a single 
ethnic group while others used a mixture of different ethnic 
groups. For example, two US prevalence study [25, 26] 
reported using both Black and White, while the study 
conducted in Spain used Caucasian females only [27]. 
Main outcomes from statistical modelling
The results of estimated prevalence of PCOS in 
general female population obtained from our model were 
shown in the Table 1. 
For the 1990 NIH, the prevalence of PCOS for 
White women was estimated at 5.5% (95% CrI: 4.8–
6.3%). The corresponding figures for Black women and 
women residing in the Middle East are 7.4% (95% CrI: 
6.3–8.7%) and 6.1% (95% CrI: 5.3–7.1%), respectively.
Using the 2003 Rotterdam, prevalence estimation is 
only feasible for Chinese women (5.6%, 95% CrI: 4.4–
7.3%) and women in the Middle East (16.0%, 95% CrI: 
13.8–18.6%). The prevalence of PCOS in the Middle East 
women almost triples that in female Chinese.
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As most studies in Middle East provide prevalence 
data using all the three major diagnostic criteria of PCOS, 
we were able to extrapolate prevalence for females in 
Middle East according to different criteria. The prevalence 
of PCOS is 6.1% (95% CrI: 5.3–7.1%) under the 1990 
NIH, 16.0% (95% CrI: 13.8–18.6%) under the 2003 
Rotterdam, and 12.0% (95% CrI: 11.3–14.2%) under the 
2006 AES for females in Middle East. The prevalence 
under Rotterdam more than doubles that under the 1990 
NIH, with the prevalence under the 2006 AES lying in-
between. 
DISCUSSION
The current study suggested that the prevalence of 
PCOS reported in the database studies are generally lower 
compared with that reported in the community studies, 
underlying the fact that PCOS is a syndrome without 
much public awareness and PCOS patients often do not 
seek care. Moreover, for the same ethnicity, the prevalence 
of PCOS was estimated to be the highest for the 2003 
Rotterdam and the lowest for the 1990 NIH. This confirms 
the results in another study where prevalence studies were 
categorised by geographical locations [28]. While Bozdag 
et al. [28] estimated continental-specific prevalence, 
it is common that nowadays individuals with different 
ethnic backgrounds reside in the same region due to 
globalisation. Therefore, our current study is advantageous 
in terms of providing ethnicity-specific estimates. 
We found that Caucasian females living in the US 
and Europe are less likely to develop PCOS compared with 
females residing in the Middle East whereas Black women 
(the majority are African-Americans and Afro-Brazilians) 
tend to have the highest risks of developing PCOS. The 
upper bound of the 95% CrI of the PCOS prevalence for 
White females is the same as the lower bound of that for 
Black females, suggesting that White and Black females 
have substantially different risks of developing PCOS. 
For Chinese women, even using the 2003 Rotterdam, the 
prevalence is merely 5.6%, which is comparable with 
the prevalence for White females under the 1990 NIH. 
The 2003 Rotterdam has the broadest spectrum, so not 
surprisingly, it is expected that the prevalence under the 
2006 AES and the 1990 NIH would be even smaller for 
Chinese females, had data been available. Therefore, 
Chinese women were suggested to be at a lower risk of 
PCOS compared with other ethnic groups. It should be 
noted that for females residing in the Middle East, the 
credible intervals of the prevalence estimates under the 
1990 NIH and the 2006 AES do not overlap, indicating 
that the prevalence of PCOS for this ethnicity is notably 
different according to these two definitions.
In general, we would expect that under the same 
diagnostic criterion of PCOS, Chinese women are at a 
lowest risk of developing PCOS, and then in an ascending 
order through Caucasian women and females residing in 
the Middle East, with Black women having the highest 
risks of developing this syndrome.
The genetic ancestry data may be used to interpret 
the phenotypic variability associated with PCOS 
to a greater extent than self-reported ethnicity [29]. 
There are evidences for genetic influence based on 
European ethnicity in women with PCOS and a genetic 
component in the phenotypic features of PCOS within a 
mixed European population [30]. It was found that the 
risk variants associated with PCOS in Korean women 
were not replicated in women of European ethnicity 
[31]. In North India, clear different phenotypes of PCOS 
were emerging, probably due to ethnic variants [32]. 
The differences in phenotype and clinical symptoms of 
PCOS related to the clinical, hormonal, and metabolic 
characteristics among various ethnic backgrounds, 
including Hispanics, African Americans, Asians, and 
Indians, need to be considered when assessing and 
treating these individuals [33]. Particularly, women 
of different ethnicities had different presentations of 
clinical hyperandrogenism such as hirsutism [34], which 
strongly suggests that clinical hyperandrogenism related 
history taking and physical examination should vary from 
patient to patient according to different ethnicities. Taken 
together, the implications of ethnic variation on screening 
and diagnosis, management priorities and response to 
treatment should be taken into account when managing 
women from distinct ethnic backgrounds, as well as in 
developing management guidelines of PCOS. 
It is also worth mentioning that even for the same 
ethnic group (i.e. women in the Middle East), there is huge 
variation in the prevalence of PCOS based on different 
diagnostic criteria. This potentially indicated the issue of 
under- or over-diagnosis of this condition at present. Given 
Table 1: Estimated prevalence of PCOS in unselected female population
Ethnicity Estimated prevalence (%) of PCOS in general female population (with 95% CrI)
1990 NIH 2003 Rotterdam 2006 AES
White (Caucasian) 5.5 (4.8–6.3) − −
Black (African-American and 
Afro-Brazilian)
7.4 (6.3–8.7) − −
Chinese − 5.6 (4.4–7.3) −
Middle East (Iranian and 
Turkish)
6.1 (5.3–7.1) 16.0 (13.8–18.6) 12.6 (11.3–14.2)
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that the major concern for women with PCOS is the long-
term metabolic risk, the clinical management of PCOS is 
suggested to be at the earliest possible when a diagnosis 
is confirmed in order to prevent the rapid conversion into 
complications such as type 2 diabetes [35]. However, on 
the contrary, healthcare workers should also be aware 
that the over-diagnosis of PCOS may exert negative 
psychological impact on women with symptoms indicative 
of PCOS. Psychological disorders may worsen some 
major symptoms of PCOS (i.e. menstrual dysfunction) and 
increase the chance for a potential case to be qualified as 
a true case. This is supported by a recent study stating that 
high stress is significantly associated with occurrence of 
severe dysmenorrhoea and irregular cycles [36]. 
The strict quality assessment resulted in only a limited 
number of eligible studies for inclusion in the statistical 
model, with a relatively small sample size reported by each 
study (e.g. between 154 and 15924). It is suggested that if 
the effect across studies is consistent, we would consider 
that the summary estimate is robust whereas in contrast, 
if there are substantial differences across studies, we may 
need to account for the dispersion. However, the problem 
arises because when there are few studies to work with, we 
may not know how the actual dispersion of studies look 
like. Therefore, we attempted to use Bayesian methods to 
address this issue. The potential drawback of this method 
is that the extrapolation of prevalence was largely driven 
by the prior distributions, which complemented the data. 
Nonetheless, although the prior distributions included may 
have some influence on the pooled estimates, we referred 
to experts’ opinions to inform our model parameters. For 
example, the prevalence of PCOS in the general population 
Figure 1: Flow chart for systematic review and statistical model.
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is expected to be within a reasonable range of 2–20% and 
this information was represented by some suitable prior 
distributions (i.e. bound the prevalence within this range 
with some variability). A notable advantage of using 
Bayesian approach is that with the application of simulation, 
the prior distributions can be updated by the observed data 
to generate some posterior distributions of the parameters 
of interest (in our case, prevalence of PCOS in different 
ethnicity). As a consequence, random sampling with a 
large sample size drawn from the posterior distributions 
was feasible, potentially providing more sensible results. 
Moreover, in our analysis, different versions of priors were 
attempted and pooled estimates were obtained from model 
averaging. Models with smaller Deviance Information 
Criterion (DIC), which indicates a better fit, were weighted 
up while models with larger DIC were weighted down. In 
this way, we did not discard information from models which 
have slightly higher DIC but give reasonable prevalence 
estimates and 95% credible interval. This improved the 
accuracy of our estimation.
As there are few instruments specifically designed 
(i.e. Newcastle-Ottawa scale for case-control and cohort 
studies) for prevalence studies, the formal evaluation 
of included studies was challenged. For example, few 
studies reported using sample size calculation and 
random sampling scheme. It was suggested by Munn. Z 
et al., [37] that the followings are all essential factors to 
be considered for prevalence studies: sampling scheme, 
sample representativeness, recruitment strategy, sample 
size calculation, description of study subjects and settings, 
response rate, standard criteria used for measurement of 
a specific condition, reliable measurement instrument, 
appropriate statistical analysis. However, few studies met 
all of the above criteria. 
Although there are some inherent challenge, the 
results from the current analysis have suggested that using 
the same diagnostic standard, Chinese women would 
have the lowest risks of developing PCOS, and then in 
an ascending order by, Caucasian women and women 
residing in the Middle East, with Black women having the 
highest risk of developing this syndrome. Considering the 
wide variation in the clinical presentations associated with 
PCOS among distinct ethnicity, there is an urgent need for 
the establishment of ethnicity-specific guidelines for this 
condition. This may help to prevent the under- or over-
diagnosis of PCOS. Further research into the community 
prevalence of PCOS in different ethnic populations 
may need to be warranted to provide sufficient data for 
prevalence extrapolation.
MATERIALS AND METHODS
Search strategy and eligibility criteria
A literature review for prevalence studies of PCOS 
was conducted in the following electronic databases: 
PubMed, The Cochrane Library, EMBASE, and CINAHL. 
These are common databases used for searching medical 
literature. The following combinations of essential search 
words were used to identify studies evaluating prevalence 
of PCOS:
((Stein-Leventhal syndrome) OR (polycystic 
ovary syndrome)) AND ((prevalence) OR 
(incidence) OR (epidemiology))
The search was restricted to English language only. 
Only studies that assessed the prevalence of PCOS in 
unselected general female population (excluding studies 
which included patients seeking medical care services 
for particular diseases, i.e. patients with type 2 diabetes 
mellitus) up to January 2017 were included. Papers with 
irrelevant titles or abstracts, for example, reviews of 
epidemiology of PCOS or, prevalence studies of PCOS-
related diseases, were excluded. The reference lists of 
included studies and relevant systematic reviews were 
searched in order to locate other potential eligible articles. 
Three reviewers (T.D., F.W. and G.B.) independently 
screened and selected the articles and disagreement was 
resolved by consensus with P.J.H. and F.Q.
Quality assessment
To ensure that the studies included in our 
statistical model provided quality data, we performed a 
methodological evaluation for the studies. As there are 
few systematic assessment criteria (i.e. Newcastle-Ottawa 
scale for case-control and cohort study) specifically 
designed for prevalence studies, we referred to both the 
Newcastle-Ottawa scale and the Joanna Briggs Institute 
prevalence critical appraisal [37] tools but modified some 
of the items within each category for methodological 
evaluation. Two independent reviewers (T.D. and G.B.) 
appraised all the articles. Inter-reviewer agreement of 0.95 
was reached and disagreement was resolved by consensus 
(T.D., F.W., G.B., P.J.H. and F.Q.). See Supplementary 
Table 2 for more details of our quality assessment.
We considered studies that had a total score of 
below 5 as poor quality ones and therefore excluded them 
from our statistical model. They were removed because 
the following important factors were not clearly stated: 
(i) age range; (ii) sample size (for studies using multiple 
ethnic groups, sample size for distinct ethnic group needs 
to be reported; (iii) diagnostic standards do not follow 
three major criteria of PCOS; (iv) ethnicity.
Data extraction
The following information was extracted from each 
available study:(i) General characteristics of the study 
(author, publication year, study period and location); 
(ii) Characteristics of sample population (recruitment 
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and sampling methods, sample size, number of PCOS 
cases, age range and ethnicity of sample population); (iii) 
Definition of PCOS (1990 NIH, Rotterdam, AES, ICD-
9 codes, medical diagnosed PCOS, clinical PCOS, self-
reported PCOS). Data extraction was performed by T.D., 
and G.B. independently. Discrepancies were resolved by 
consensus (T.D., F.W., G.B., P.J.H. and F.Q.).
Studies were categorised according to geographical 
locations, which may potentially distinguish different 
ethnic groups, as it seems reasonable to assume that there 
is ethnic variation in the prevalence of PCOS [15].
We referred to the classification of ethnic category 
by National Health Service in the UK [38] and categorised 
studies strictly by ethnicity. All studies providing 
prevalence data for the same ethnicity were classified 
into the same category regardless of country origin. For 
studies where sample population consisted of more than 
one ethnicity (i.e. both Black and White), we used them 
repeatedly and extracted raw number of PCOS cases 
and corresponding sample sizes for different ethnicity 
separately. The raw numbers of PCOS in the sample of 
each study were extracted to be used for our model. For 
studies where the number of PCOS cases is not provided 
and the prevalence of PCOS is based on simulations, the 
raw number of PCOS cases was calculated and rounded 
to the nearest integer. Studies with an asterisk in the 
Supplementary Table 1 were included in our model.
Data analysis
We analysed the data using a Bayesian hierarchical 
model. In a nutshell, the Bayesian approach to statistical 
inference [39–41] is based on the premise that both 
sampling variability (i.e. due to individual variations in 
the observed data) and epistemic uncertainty (i.e. due to 
our imperfect knowledge of model parameters, such as 
population prevalence) are modelled using probability 
distributions. These are used to describe the state of 
science currently available. Before observing the data, the 
modellers specify a ‘prior’ distribution for the quantity of 
interest, typically unobservable population parameters, 
to represent the current uncertainty. This prior is updated 
into a ‘posterior’ distribution through the application 
of Bayesian theorem, after the data are observed. The 
formal inclusion of prior information can be beneficial 
particularly in cases where the observed evidence is 
limited and non-conclusive. Practically, Bayesian analysis 
is typically performed using a simulation approach 
in which samples from the posterior distributions are 
obtained using computer algorithms. These can be used to 
quantify the updated level of uncertainty in the parameters 
of interest, e.g. by computing relevant summaries such as 
the mean or the interval containing most (e.g. 95%) of the 
posterior distribution. 
We use a ‘hierarchical’ Bayesian model with a 
two-fold objective: firstly, we want to complement the 
limited information obtained by the literature review (see 
Results section) by explicitly modelling the prevalence 
parameters so as to reflect the assumption that the 
prevalence of PCOS is within a reasonable range in the 
general population, regardless of ethnicity. Secondly, the 
inclusion of ‘random effects’ (which renders our model 
‘hierarchical’) allow us to account for correlation induced 
by clustering, e.g. within geographical areas or common 
background characteristics. 
In our analysis, the prevalence estimates were 
obtained using the mean and the 2.5th and 97.5th percentiles 
of the posterior distribution (95% credible interval, CrI); 
these can be considered as a Bayesian counterpart to the 
lower and upper bound of the traditional 95% confidence 
interval. We attempted different versions of priors for our 
model to assess the robustness of the results. This includes 
normal distribution prior for ethnicity-specific prevalence 
at population level. The nature of the normal distribution 
allows certain degree of variability around a centred mean 
and we considered different mean prevalence within a 
reasonable range of 2–20% (A normal distribution with 
a mean of 0.1 and a variance of 0.0001 represents that 
the population level mean prevalence is 10% with a 
standard deviation from the mean of 0.01 (i.e. 95% CI: 
8–12%)). The prior for the population-level prevalence 
is complemented by uniform (A Uniform distribution 
assumes that all values within a range are equally likely) or 
half-Cauchy (A half-Cauchy distribution is characterised 
by heavy tails (compared to a normal distribution) to allow 
for outliers and accommodating small variances close to 
zero (in our case, the variance for the population level 
mean prevalence is considered to be small as the mean 
prevalence itself is not large)) prior distribution for the 
population-level variance. The different specifications 
of our model (upon varying the prior distributions) were 
assessed using the DIC [42]– this is a measure of model 
fitting, with lower values indicating a better fit. However, 
because of the limited amount of information, rather than 
simply selecting one model (which could well be the least 
worse in a set of not entirely satisfactory models), we 
combined the possible formulations by weighting them 
using a function of their computed DIC. This produced 
a ‘model average’ describing our best assessment, given 
the limited evidence observed and a set of reasonable 
prior assumptions. Detailed explanations for our Bayesian 
hierarchical model and prior specifications are provided in 
Supplementary Figure 1. 
The analyses were performed using simulation 
methods in JAGS, a specialised software used to obtain 
simulations from arbitrarily complex models, interfaced 
with R version 3.3.2 (The R Foundation for Statistical 
Computing).Two Markov chains ran simultaneously with 
different initial values selected arbitrarily for convergence 
purpose. A total of 40,000 simulations per chain were 
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